CD8A and neoplasm: In melanoma, the replacement of LBH589 with romidepsin for combination therapy with I-BET151 promotes apoptosis and changes the expression of IL-6/JAK/STAT-related genes, which increases the response frequency of CD8+ T cells in mice vaccinated with OVA+CpG tumor vaccine and improves the treatment efficacy and preventive protection of the vaccine (99).